Back to results
US 11,079,395 B2Granted
Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
AssigneesAbbott Laboratories, Emory University
InventorsAgim Beshiri, Arshed A. Quyyumi
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on determining cardiac troponin (cTnI) levels in a human at rest and during or after exercise.
Claims9
A method comprising:
- (a) detecting a resting level of cardiac troponin I (cTnI) of at least 4 ng/mL in a blood, serum, or plasma sample obtained from a human with coronary artery disease (CAD),
- (b) detecting the level of cTnI in a blood, serum, or plasma sample obtained from the human during or after exercise,
- (c) measuring at least a 10% increase in the cTnI level during or after exercise as compared the resting cTnI level, which indicates that the human is likely to experience a major adverse cardiovascular event (MACE), and
- (d) administering to the human a therapeutically effective amount of at least one statin, at least one β-blocker, at least one nitrate, at least one phosphodiesterase (PDE) inhibitor, at least one calcium channel blocker, at least one cGMP stimulator, at least one sinus node inhibitor, at least one Rho kinase inhibitor, arginine, allopurinol, testosterone, or any combinations thereof.
1 more element
Dependencies are inferred from the claim text.